Antipsychotic treatment patterns in Alzheimer’s disease patients with agitation: a cohort study using the UK clinical practice research datalink

References

• 2015 Alzheimer's disease facts and figures. Alzheimer's & Dementia: The Journal of the Alzheimer's Association. 2015;11(3):332–384.
   PubMed Web of Science ®Google Scholar
• Prince M, Bryce R, Albanese E, et al. The global prevalence of dementia: a systematic review and meta analysis. Alzheimers Dement. 2013;9(1):63–75 e2.
   PubMed Web of Science ®Google Scholar
• Prince M, et al. “Dementia UK: Update,” 2014.
   Google Scholar
• Finkel SI, Costa e Silva J, Cohen G, et al. Behavioral and psychological signs and symptoms of dementia: a consensus statement on current knowledge and implications for research and treatment. Int Psychogeriatr. 1996;8(Suppl 3):497–500.
   PubMedGoogle Scholar
• Vik-Mo AO, Giil LM, Ballard C, et al. Course of neuropsychiatric symptoms in dementia: 5-year longitudinal study. Int J Geriatr Psychiatry. 2018;33(10):1361–1369.
   PubMed Web of Science ®Google Scholar
• Barnes TR, Banerjee S, Collins N, et al. Antipsychotics in dementia: prevalence and quality of antipsychotic drug prescribing in UK mental health services. Br J Psychiatry. 2012;201(3):221–226.
   PubMed Web of Science ®Google Scholar
• Testad I, Auer S, Mittelman M, et al. Nursing home structure and association with agitation and use of psychotropic drugs in nursing home residents in three countries: Norway, Austria and England. Int J Geriat Psychiatry. 2009;25(7):725–731.
   Web of Science ®Google Scholar
• Cummings J, Mintzer J, Brodaty H, et al. Agitation in cognitive disorders: International psychogeriatric association provisional consensus clinical and research definition. Int Psychogeriatr. 2015;27(1):7–17.
   PubMed Web of Science ®Google Scholar
• MHRA, “Antipsychotic medicines: licensed products, uses and side effects – GOV.UK,” 2005. Available from: https://www.gov.uk/government/publications/antipsychotic-medicines-licensed-products-uses-and-side-effects.
   Google Scholar
• Douglas IJ, Smeeth L. Exposure to antipsychotics and risk of stroke: self controlled case series study. BMJ. 2008;337:a1227.
   PubMedGoogle Scholar
• Schneider LS, Dagerman K, Insel PS. Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry. 2006;14(3):191–210.
   PubMed Web of Science ®Google Scholar
• Mueller C, John C, Perera G, et al. Antipsychotic use in dementia: the relationship between neuropsychiatric symptom profiles and adverse outcomes. Eur J Epidemiol. 2021; 36(1):89–101.
   PubMed Web of Science ®Google Scholar
• Sturm AS, Trinkley KE, Porter K, et al. Efficacy and safety of atypical antipsychotics for behavioral symptoms of dementia among patients residing in long-term care. Int J Clin Pharm. 2018;40(1):135–142.
   PubMed Web of Science ®Google Scholar
• Langballe EM, Engdahl B, Nordeng H, et al. Short- and long-term mortality risk associated with the use of antipsychotics among 26,940 dementia outpatients: a population-based study. Am J Geriatr Psychiatry. 2014;22(4):321–331.
   PubMed Web of Science ®Google Scholar
• Maust DT, Kim HM, Seyfried LS, et al. Antipsychotics, other psychotropics, and the risk of death in patients with dementia: number needed to harm. JAMA Psychiatry. 2015;72(5):438–445.
   PubMed Web of Science ®Google Scholar
• Trifiró G, Sultana J, Spina E. Are the safety profiles of antipsychotic drugs used in dementia the same? An updated review of observational studies. Drug Saf. 2014;37(7):501–520.
   PubMed Web of Science ®Google Scholar
• Banerjee S. “The use of antipsychotic medication for people with dementia: time for action,” 2012.
   Google Scholar
• Martinez C, Jones RW, Rietbrock S. Trends in the prevalence of antipsychotic drug use among patients with Alzheimer's disease and other dementias including those treated with antidementia drugs in the community in the UK: a cohort study. BMJ Open. 2013;3(1):e002080.
   PubMed Web of Science ®Google Scholar
• Herrett E, Gallagher AM, Bhaskaran K, et al. Data resource profile: Clinical Practice Research Datalink (CPRD). Int J Epidemiol. 2015;44(3):827–836.
   PubMed Web of Science ®Google Scholar
• Ferretti L, McCurry SM, Logsdon R, et al. Anxiety and Alzheimer's disease. J Geriatr Psychiatry Neurol. 2001;14(1):52–58.
   PubMed Web of Science ®Google Scholar
• Enache D, Winblad B, Aarsland D. Depression in dementia: epidemiology, mechanisms, and treatment. Curr Opin Psychiatry. 2011;24(6):461–472.
   PubMed Web of Science ®Google Scholar
• Becker E, Orellana Rios CL, Lahmann C, et al. Anxiety as a risk factor of Alzheimer's disease and vascular dementia. Br J Psychiatry. 2018;213(5):654–660.
   PubMed Web of Science ®Google Scholar
• 2018. Dementia: assessment, management and support for people living with dementia and their carers | Guidance and guidelines | NICE. [Online] Available: https://www.nice.org.uk/guidance/ng97/chapter/Recommendations#pharmacological-interventions-for-dementia.
   Google Scholar
• Lamy FX. “The use of adjunctive antipsychotics to treat depression in UK primary care,”; [cited 15 Mar 2017]. Available from:
   Google Scholar
• Porsteinsson AP, Antonsdottir IM. An update on the advancements in the treatment of agitation in Alzheimer's disease. Expert Opin Pharmacother. 2017;18(6):611–620.
   PubMed Web of Science ®Google Scholar
• Defrancesco M, Marksteiner J, Fleischhacker WW, et al. Use of benzodiazepines in Alzheimer’s disease: a systematic review of literature. Int J Neuropsychopharmacol. 2015;18(10):pyv055.
   PubMed Web of Science ®Google Scholar
• Huhn M, Nikolakopoulou A, Schneider-Thoma J, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet. 2019;394(10202):939–951.
   PubMed Web of Science ®Google Scholar
• Donegan K, Fox N, Black N, et al. Trends in diagnosis and treatment for people with dementia in the UK from 2005 to 2015: a longitudinal retrospective cohort study. Lancet Public Health. 2017;2(3):e149–e156.
   PubMed Web of Science ®Google Scholar
• Seshadri S, Zornberg GL, Derby LE, et al. Postmenopausal estrogen replacement therapy and the risk of Alzheimer disease. Arch Neurol. 2001;58(3):435–440.
   PubMedGoogle Scholar
• Black N, Dixon J, Tan S, et al. Improving healthcare for people with dementia in England: good progress but more to do. J R Soc Med. 2015;108(12):478–481.
   PubMed Web of Science ®Google Scholar